Conatumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Conatumumab
Accession Number
DB11646
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
AMG 655 / AMG-655 / AMG655
Categories
UNII
1P48L61KM0
CAS number
896731-82-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Conatumumab.
AbituzumabThe risk or severity of adverse effects can be increased when Conatumumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Conatumumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Conatumumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Conatumumab.
AducanumabThe risk or severity of adverse effects can be increased when Conatumumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Conatumumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Conatumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Conatumumab.
AmatuximabThe risk or severity of adverse effects can be increased when Conatumumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911222
Wikipedia
Conatumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDiffuse Large Cell Lymphoma / Low Grade Lymphoma / Lymphoma, Hodgkins / Malignant Lymphomas / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentRelapsed Epithelial Ovarian Cancer / Relapsed Fallopian Tube Cancer / Relapsed Primary Peritoneal Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas / Pancreatic Cancer Metastatic1
1, 2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancer (MCRC) / Oncology / Rectal Carcinoma1
1, 2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancer (MCRC) / Rectal Carcinoma1
1, 2CompletedTreatmentLocally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma / Sarcomas / Soft Tissue Sarcoma (STS)1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentColorectal Cancers / Locally Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Metastatic Cancers / Ovarian Cancer / Sarcomas / Tumors, Solid1
1, 2WithdrawnTreatmentMalignant Neoplasm of Pancreas1
2Active Not RecruitingTreatmentAdvanced Solid Tumors / Carcinoids / Colorectal Cancers / Locally Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Lymphomas / Metastatic Cancers / Sarcomas / Tumors, Solid1
2CompletedTreatmentMetastatic Colorectal Cancer (MCRC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:37 / Updated on December 02, 2019 09:07